By Kathleen Gallagher of the Journal Sentinel
Posted: May. 5, 2009
Pfizer Inc. said Tuesday that it has signed a license with the Wisconsin Alumni Research Foundation to use human embryonic stem cells for the development of new drug therapies. With annual revenue of more than $48 billion,
Pfizer is the biggest of the 35 companies to sign an embryonic stem cell license with the foundation, said Andy DeTienne, WARF's licensing manager for stem cells. Financial terms were not disclosed.
